Apolipoprotein E, Human Plasma, Very Low-Density Lipoprotein

Name: Apolipoprotein E, Human Plasma, Very Low-Density Lipoprotein
Brand: MM

Native apolipoprotein E from human plasma. A major component of VLDL and IDL. Serves as a major cholesterol carrier. Essential for the normal catabolism of triglyceride-rich lipoprotein constituents.

Synonym(s):

Apo E

Select a Size

All Photos(1)

About This Item

NACRES:

NA.25

UNSPSC Code:

12352202

Product Name

Apolipoprotein E, Human Plasma, Very Low-Density Lipoprotein, Native apolipoprotein E from human plasma. A major component of VLDL and IDL. Serves as a major cholesterol carrier. Essential for the normal catabolism of triglyceride-rich lipoprotein constituents.

assay

≥95% (SDS-PAGE)

form

liquid

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze
avoid repeated freeze/thaw cycles

shipped in

wet ice

storage temp.

−20°C

Quality Level

100

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Toxicity: Standard Handling (A)

General description

Native apolipoprotein E from human plasma. A component of VLDL and of a subclass of HDL. Present in normal plasma at concentrations of 50 µg/ml. Serves as a ligand for LDL receptors, where it participates in the transport and redistribution of cholesterol and other lipids. Also functions in immunoregulation and cell growth differentiation. Inhibits mitogen-induced T-lymphocyte proliferation and modulation of smooth muscle cell differentiation.

Other Notes

Kelly, M.E., et al. 1994. Cell Immunol. 159, 124.
Mahley, R.W. 1988. Science 240, 622.
Rall, S.C., et al. 1986. Methods Enzymol. 128, 273.

Packaging

Please refer to vial label for lot-specific concentration.

Physical form

In 50 mM NH₄HCO₃, pH 8.0.

Preparation Note

Following initial thaw, aliquot and freeze (-20°C).

Prepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Practical detection of a definitive biomarker panel for Alzheimer's disease; comparisons between matched plasma and cerebrospinal fluid.

Joanna L Richens et al.

International journal of molecular epidemiology and genetics, 5(2), 53-70 (2014-06-25)

Previous mass spectrometry analysis of cerebrospinal fluid (CSF) has allowed the identification of a panel of molecular markers that are associated with Alzheimer's disease (AD). The panel comprises Amyloid beta, Apolipoprotein E, Fibrinogen alpha chain precursor, Keratin type I cytoskeletal

Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach.

Jian-Ying Zhou et al.

Journal of proteome research, 9(10), 5133-5141 (2010-08-12)

The discovery of biomarkers for neurodegenerative diseases will have a major impact on the efficiency of therapeutic clinical trials and may be important for understanding basic pathogenic mechanisms. We have approached the discovery of protein biomarkers for amyotrophic lateral sclerosis

Transferrin coated nanoparticles: study of the bionano interface in human plasma.

Andrzej S Pitek et al.

PloS one, 7(7), e40685-e40685 (2012-07-26)

It is now well established that the surface of nanoparticles (NPs) in a biological environment is immediately modified by the adsorption of biomolecules with the formation of a protein corona and it is also accepted that the protein corona, rather